13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001400240
Total reported value
$1.5B
$1.5B
4 檔
19.0%
During the Q3 2025 filing period, Flagship Pioneering, LLC (CIK: 0001400240) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.5B across 4 reported positions.
Flagship Pioneering, LLC executed strategic sector rebalancing during Q3 2025, establishing 1 new positions while fully exiting 1 holdings and trimming 0 positions.
In terms of portfolio concentration, the top 5 core holdings (including MRNA, SANA, FHTX) accounted for 19.0% of total reported equity market value during Q3 2025.
Top New Position Initiated
MCRB
市值: $22.2M
Top Position Liquidated / Trimmed
MCRB1EUR
前期市值: $16.2M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna Inc | Stock-Healthcare | 40.89% | +0.81% | — | |
| 2 | SANA | Sana Biotechnology Inc | Stock-Other | 30.33% | -0.53% | — | |
| 3 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 21.18% | -1.20% | — | |
| 4 | MCRB | Seres Therapeutics Inc | Stock-Other | 7.60% | -0.29% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SANA | Sana Biotechnology Inc | +12.5% | — | Unchanged |
| 2 | FHTX | Foghorn Therapeutics Inc | +1.6% | — | Unchanged |
| 3 | MRNA | Moderna Inc | -14.8% | — | Unchanged |
| 4 | MCRB | Seres Therapeutics Inc | — | NEW | New buy |
| 5 | MCRB1EUR | Seres Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Flagship Pioneering, LLC reported a total U.S. public equity portfolio value of $1.5B across 4 disclosed positions in Q3 2025.
During Q3 2025, Flagship Pioneering, LLC's top holdings by market value included MRNA (40.9%)、SANA (30.3%)、FHTX (21.2%). The largest single position, MRNA, represented 40.9% of total portfolio value.
In Q3 2025, Flagship Pioneering, LLC made 2 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.